Drug Search Results
More Filters [+]

Enarodustat

Alternative Names: enarodustat, jtz-951, jtz951, jtz 951, SAL0951, SAL 0951, SAL-0951
Latest Update: 2024-08-13
Latest Update Note: Clinical Trial Update

Product Description

The orally active hypoxia inducible factor-proly hydroxylase (HIF-PH) inhibitor enarodustat (ENAROY¨, Japan Tobacco) is being developed as an alternative to injectable erythropoietin stimulating agents such as epoetin and darbepoetin for the treatment of anaemia associated with chronic kidney disease (CKD). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33320297/)

Mechanisms of Action: HIF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan | Korea

Approved Indications: None

Known Adverse Events: None

Company: Japan Tobacco
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Enarodustat

Countries in Clinic: China, Japan

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Anemia

Phase 1: Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2071210099

P1

Completed

Kidney Diseases|Anemia

2022-06-30

CTR20202454

P1

Not yet recruiting

Anemia

None

CTR20232186

P3

Not yet recruiting

Anemia

None

CTR20202445

P3

Recruiting

Anemia

None

Recent News Events